EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Fluoroquinolone‐Associated Peripheral and Central Nervous System‐Related Disorders: A Large German Claims‐Based Cohort Study

Julia Wicherski iD, Jonas Peltner, Cornelia Becker, Katrin Schüssel, Gabriela Brückner, Andreas Schlotmann, Helmut Schröder, Winfried V Kern, Britta Haenisch iD

European Journal of Neurology · 2026

DOI: 10.1111/ene.70585 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Julia Wicherski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Federal Institute for Drugs and Medical Devices (BfArM), Research Division, Pharmacoepidemiology, Bonn, Germany. Hauptthemen laut MEDLINE: Fluoroquinolones, Anti-Bacterial Agents, Peripheral Nervous System Diseases, Central Nervous System Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To examine the association between newly prescribed fluoroquinolones (FQ) and the occurrence of polyneuropathy and certain neuropsychiatric events.

Methods

German statutory health insurance‐based cohort study (2013–2019) of patients exposed to FQ compared to different reference antibiotics. Patients with an incident antibiotic prescription were followed up for 365 days after initial dispensing. Outcomes were defined by incident diagnoses of polyneuropathy/other peripheral nervous system‐related diseases (PNS), depression/other affective disorders (DEP), mood‐related symptoms (MOOD), somnolence/stupor/coma (SSC), and consciousness‐related symptoms (CONSCIOUS). Piece‐wise exponential additive mixed models adjusted for person‐time, age, comorbidities, year, and quarter of cohort entry were applied.

Results

The outcome‐specific cohorts included 10.7–14.3 million antibiotic episodes of which 1.7% had incident PNS, 4.8% DEP, 1.5% MOOD, 0.6% SSC, 0.8% CONSCIOUS. Relative risks for these outcomes ranged from 1.04 to 1.10 for FQ versus reference antibiotics. Stratified by gender and age groups, relative risk for PNS was high in ≤ 39‐year‐old males (aHR = 1.31 [95% 1.19; 1.45]), for MOOD and CONSCIOUS in 40–69‐year‐old females (aHR = 1.12 [1.08; 1.15], aHR = 1.14 [1.09; 1.19]) for DEP in ≥ 70‐year‐old males (aHR = 1.16 [1.14; 1.19]), whereas relative risk for SSC was high in ≤ 39‐year‐old females (aHR = 1.24 [1.10; 1.40]). FQ‐associated PNS was mainly comprised of drug‐induced polyneuropathy (aHR = 1.68 [1.58; 1.79]). Relative risks for each endpoint varied by choice of active comparator.

Conclusions

FQ episodes were associated with an increased risk for neurological and neuropsychiatric events, especially within the first 92 days after initial dispensing. Risk estimates vary by age and gender subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesAnti-Bacterial AgentsPeripheral Nervous System DiseasesCentral Nervous System DiseasesHumansMaleFemaleGermanyCohort StudiesMiddle AgedAdultAged

Stichwörter der Autor:innen

active comparator new user designadministrative cohortadverse drug reactionsfluoroquinolonesreal‐world data

Substanzen

FluoroquinolonesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Federal Institute for Drugs and Medical Devices (BfArM), Research Division, Pharmacoepidemiology, Bonn, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), Pharmacoepidemiology in Neurodegenerative Disorders, Bonn, Germany.
  • Research Institute of AOK (WIdO), Berlin, Germany.
  • Division of Infectious Diseases, Department of Medicine II, University of Freiburg Faculty of Medicine and Medical Centre, Freiburg, Germany.
  • Center for Translational Medicine, University of Bonn, Bonn, Germany.

ORCID-Profile: Julia Wicherski, Britta Haenisch

Zitieren

APA

Wicherski, J., Peltner, J., Becker, C., Schüssel, K., Brückner, G., Schlotmann, A., Schröder, H., Kern, W. V., & Haenisch, B. (2026). Fluoroquinolone‐Associated Peripheral and Central Nervous System‐Related Disorders: A Large German Claims‐Based Cohort Study. European Journal of Neurology. https://doi.org/10.1111/ene.70585

Vancouver

Wicherski J, Peltner J, Becker C, Schüssel K, Brückner G, Schlotmann A, et al. Fluoroquinolone‐Associated Peripheral and Central Nervous System‐Related Disorders: A Large German Claims‐Based Cohort Study. European Journal of Neurology. 2026. doi:10.1111/ene.70585

BibTeX
@article{Wicherski2026,
  author = {Wicherski, Julia and Peltner, Jonas and Becker, Cornelia and Schüssel, Katrin and Brückner, Gabriela and Schlotmann, Andreas and Schröder, Helmut and Kern, Winfried V and Haenisch, Britta},
  title = {Fluoroquinolone‐Associated Peripheral and Central Nervous System‐Related Disorders: A Large German Claims‐Based Cohort Study},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70585}
}
Kostenlos starten →